Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ST101 by Sapience Therapeutics for Sarcomas: Likelihood of Approval
ST101 is under clinical development by Sapience Therapeutics and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
ST101 by Sapience Therapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval
ST101 is under clinical development by Sapience Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
ST101 by Sapience Therapeutics for Gastrointestinal Tract Cancer: Likelihood of Approval
ST101 is under clinical development by Sapience Therapeutics and currently in Phase II for Gastrointestinal Tract Cancer. According to GlobalData,...
ST101 by Sapience Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
ST101 is under clinical development by Sapience Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
ST101 by Sapience Therapeutics for Signet Ring Cell Squamous Cell Carcinoma: Likelihood of Approval
ST101 is under clinical development by Sapience Therapeutics and currently in Phase II for Signet Ring Cell Squamous Cell Carcinoma....